Publications by authors named "Anthony Gschwend"

Article Synopsis
  • A study in France, called the SISCOVID study, looked at lung health in patients who recovered from COVID-19 three and six months after being discharged from the hospital.
  • Of the 320 patients assessed, many faced ongoing breathing issues and lung function problems, with those who had severe COVID-19 experiencing more significant complications.
  • The findings indicate that over half of the patients had persistent dyspnoea and lung impairment at six months, highlighting the importance of ongoing monitoring and research into the long-term effects of COVID-19 on lung health.
View Article and Find Full Text PDF

Acute respiratory distress syndrome (ARDS) is a diffuse lung injury that leads to a severe acute respiratory failure. Traditional diagnostic criteria for pulmonary hypertension (PH), in this situation, may be unreliable due to the effects of positive pressure ventilation and vasoactive agents. The aim of this study is to describe the hemodynamic characteristics of PH secondary to ARDS, in relation with respiratory parameters.

View Article and Find Full Text PDF

Cladophialophora bantiana brain abscesses are rare, but are frequently and quickly lethal in transplanted patients. We report the case of a 63-year-old man who had undergone lung transplantation for chronic obstructive pulmonary disease and presented with headaches and a neurological deficit. Magnetic resonance imaging revealed multiple brain abscesses.

View Article and Find Full Text PDF

Erlotinib has been approved as second-line treatment in patients with non-small cell lung cancer (NSCLC) experiencing relapse after first-line platinum-based chemotherapy. Herein, we report two occurrences of erlotinib-associated gastrointestinal perforation (GIP) in NSCLC patients. Two patients aged 60 and 79 years received erlotinib as third- and second-line NSCLC treatment, respectively.

View Article and Find Full Text PDF

We report two cases of acute hepatitis induced by crizotinib in patients with ALK-rearranged non-small cell lung cancer (NSCLC) who were treated after by a second generation of ALK inhibitor without any incident. These cases suggest that ceritinib could be used as an alternative agent when crizotinib is responsible for hepatitis.

View Article and Find Full Text PDF